PolyTherics’ PEGylation technology will be combined with Zealand’s peptide candidates.
PolyTherics and Zealand Pharma entered a research collaboration focused on the development of PEGylated forms of peptide-based therapeutics against metabolic, cardiovascular, and gastrointestinal diseases.
The partnership will apply PolyTherics’ PEGylation technologies to specific peptide candidates discovered by Zealand. Funding will come from the EUREKA Eurostars Program, which provides support to SMEs.
The companies say their collaboration is expected to run for 24 months. During the first year they will carry out experimental research, and over the second 12 months they aim to select lead candidates for preclinical development.
